Engineered Killer Immune Cells Target Tumours and their Immunosuppressive Allies

Articles

Jul 7, 2020

Natural killer immune cells engineered to target the PD-L1 molecule can directly kill tumour cells in mice and reduce the numbers of immunosuppressive cells harbouring PD-L1 in mice and humans.

Read Article

Contact us at

+1-844-MY NK CELLS (+1-844-696-5235)

Visit Newsroom

Solutions for Patients

ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Next-generation adenovirus-vectored anti-cancer vaccines make appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research.

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

About Us